| Literature DB >> 35264025 |
Sofia Mendes Sieczkowska1,2, Camilla Astley1,2, Isabela Gouveia Marques1,2, Amanda Yuri Iraha1,2, Tathiane Christine Franco1,2, Bianca Pires Ihara3, Sofia Simão Martins Lavorato3, Livia Lindoso3, Debora Narumi Demitrol Setoue3, Nicolas Yamada Tanigava2, Lucia Maria Arruda Campos3, Rosa Maria Rodrigues Pereira2, Nadia Emi Aikawa2,3, Hamilton Roschel1,2, Ligia Bruni Queiroz3, Guilherme V Polanczyk3, Clovis Artur Silva2,3, Bruno Gualano1,2,4.
Abstract
OBJECTIVES: To investigate the perceptions and acceptability of a home-based exercise intervention in systemic lupus erythematosus (JSLE) and juvenile idiopathic arthritis (JIA) adolescent patients during the COVID-19 pandemic, and to explore the effects of the intervention on health-related quality of life (HRQoL), sleep quality, and mental health conditions parameters.Entities:
Keywords: pediatric rheumatic diseases; physical activity; physical training; quality of life
Mesh:
Year: 2022 PMID: 35264025 PMCID: PMC8914298 DOI: 10.1177/09612033221083273
Source DB: PubMed Journal: Lupus ISSN: 0961-2033 Impact factor: 2.911
Figure 1.Flow charts of patients with juvenile systemic lupus erythematosus and patients with juvenile idiopathic arthritis.
Patients’ demographic characteristics and disease-related parameters in patients with juvenile systemic lupus erythematosus and juvenile idiopathic arthritis.
| Characteristics | JSLE n= (21) | JIA n= (30) |
|---|---|---|
| Age (years) | 15.8 (2.25) | 14.5 (2.27) |
| Height (m) | 1.61 (0.09) | 1.58 (0.07) |
| Bodyweight (kg) | 61.1 (18.8) | 62.2 (15.6) |
| BMI (kg/m2) | 23.1 (5.27) | 24.3 (5.58) |
| Female, n (%) | 16 (76.1) | 24 (80) |
| Disease time (years) | 6.45 (3.90) | 5.20 (4.78) |
| Age at the disease onset (years) | 9.66 (3.48) | 9.36 (3.68) |
| Prednisone, n (%) | 11 (52%) | 3 (10%) |
| Dosage mg/day | 10 (5–22.5) | 10 (10–17.5) |
| Methotrexate, n (%) | 4 (19%) | 8 (27%) |
| Dosage mg/day | 17.5 (11.2–23.7) | 25 (20–25) |
| Leflunomide, n (%) | 1 (5%) | 11 (30%) |
| Dosage mg/day | 20 | 20 (20–20) |
| HCQ, n (%) | 20 (95%) | 1 (3%) |
| Dosage mg/day | 400 (200–400) | 200 (200–200) |
| Adalimumab n (%) | 0 (0) | 3 (%) |
| Dosage mg/day | 40 (40–40) | |
| Etanercept, n (%) | 0 (0) | 3 (10%) |
| Dosage mg/day | 50 (50–50) |
Values are described in mean (SD) or median ITQ (25–75). Abbreviations: JSLE: juvenile systemic lupus erythematosus; JIA: juvenile idiopathic arthritis; BMI: body mass index; HCQ: hydroxychloroquine.
Perceptions of adolescents with systemic lupus erythematosus on a home-based exercise program during COVID-19 pandemic.
| Themes | JSLE Patient’s | Quotes |
|---|---|---|
| I | ||
| II | ||
| III | ||
| IV | ||
| V | ||
| Appropriate trainer supervision | II | |
| III | ||
| IV | ||
| V | ||
| VI | ||
| VII | ||
| Motivators and facilitators to the program | II | |
| III | ||
| IV | ||
| V | ||
| VI | ||
| VII | ||
| VIII | ||
| Barriers of the program | I | |
| II | ||
| III | ||
| IV | ||
| VII | ||
| VIII | ||
| Health benefits | I | |
| II | ||
| III | ||
| IV | ||
| V | ||
| VI | ||
| VII | ||
| VIII | ||
| Patients’ suggestions to improve the program | III | |
| V | ||
| VI | ||
| VII |
Perceptions of adolescents with juvenile idiopathic arthritis on a home-based exercise program during COVID-19 pandemic.
| Themes | JIA Patient’s | Quotes |
|---|---|---|
| I | ||
| II | ||
| III | ||
| IV | ||
| V | ||
| VI | ||
| VII | ||
| Appropriate trainer supervision | III | |
| VI | ||
| VII | ||
| VIII | ||
| Motivators and facilitators to the program | I | |
| II | ||
| III | ||
| VI | ||
| VII | ||
| VIII | ||
| IX | ||
| X | ||
| XI | ||
| XII | ||
| Barriers of the program | I | |
| II | ||
| III | ||
| IV | ||
| VII | ||
| IX | ||
| X | ||
| XII | ||
| XIII | ||
| Health benefits | III | |
| IV | ||
| VI | ||
| VII | ||
| VIII | ||
| IX | ||
| XI | ||
| XIII | ||
| XIV | ||
| Patients’ suggestions to improve the program | I | |
| V | ||
| VI | ||
| X | ||
| XII | ||
| XIII |
Effects of a 12-week home-based exercise training program on Strengths and Difficulties Questionnaire (SDQ), Pediatric Quality of Live Inventory 4.0 (PedsQL 4.0), and Pittsburgh Sleep Quality Index (PSQI) in adolescents with systemic lupus erythematosus.
| Control Group | Intervention Group | p value | |||||
|---|---|---|---|---|---|---|---|
| Domains (score) | Mean Baseline (95% CI) | Mean Post (95% CI) | Mean Baseline (95% CI) | Mean Post (95% CI) | TIME | GROUP | INT |
| Total difficulties score (0; 40) | 11.0 (6.7; 15.2) | 9.8 (5.49; 14.2) | 18.4 (13.5; 23.3) | 16.1 (11.2; 21.0) | 0.16 | 0.02 | 0.64 |
| Emotional problems (0; 10) | 4.2 (2.5; 5.8) | 3.40 (1.70; 5.0) | 5.9 (3.9; 7.8) | 4.8 (2.9; 6.8) | <0.01 | 0.19 | 0.69 |
| Conduct problems (0; 10) | 1.9 (1.0; 2.8) | 1.23 (0.3; 2.1) | 2.5 (1.5; 3.5) | 2.8 (1.8; 3.9) | 0.58 | 0.06 | 0.11 |
| Hyperactivity/inattention (0; 10) | 3.0 (1.3; 4.6) | 2.8 (1.1; 4.4) | 5.8 (4.0; 7.7) | 5.3 (3.4; 7.2) | 0.43 | 0.02 | 0.69 |
| Peer problems (0; 10) | 1.9 (0.9; 2.9) | 2.2 (1.3; 3.4) | 3.0 (1.8; 4.1) | 3.0 (1.8; 4.1) | 0.43 | 0.24 | 0.43 |
| Prosocial (0; 10) | 7.6 (6.42; 8.9) | 8.7 (7.5; 10.0) | 8.0 (6.5; 9.4) | 8.1 (6.6; 9.5) | 0.08 | 0.70 | 0.14 |
| Impact score (0; 10) | 0.9 (0.01; 1.8) | 1.3 (0.39; 2.2) | 1.5 (0.5; 2.6) | 1.6 (0.6; 2.7) | 0.40 | 0.42 | 0.64 |
| PedsQL total scale score (0; 100) | 72.3 (63.0; 81.7) | 78.5 (69.2; 87.9) | 65.9 (55.1; 76.7) | 66.6 (55.8; 77.4) | 0.24 | 0.36 | 0.36 |
| Physical health summary score (0; 100) | 71.1 (60.1; 82.1) | 81.5 970.5; 92.5) | 69.8 (56.4; 81.8) | 69.1 (56.4; 81.8) | 0.11 | 0.38 | 0.07 |
| Emotional functioning (0; 100) | 65.4 (52.4; 78.5) | 61.25 (48.2; 74.3) | 49.4 (34.4; 64.5) | 55.6(40.5; 70.6) | 0.78 | 0.24 | 0.15 |
| Social functioning (0; 100) | 87.5 (76.4; 98.6) | 88.7 9(77.6; 99.8) | 78.33 (65.5; 91.1) | 78.9 (66.1; 91.7) | 0.83 | 0.20 | 0.93 |
| School functioning (0; 100) | 67.9 (57.1; 78.7) | 76.82 (65.9; 87.4) | 57.78 (45.3;70.2) | 57.8 (45.3;70.2) | 0.33 | 0.04 | 0.33 |
| Psychosocial health summary (0; 100) | 73.6 (63.9;83.2) | 76.4 (65.9 85.2) | 61.8 (50.7; 73.0) | 64.1 (52.9; 75.2) | 0.51 | 0.08 | 0.96 |
| PSQI total score (0; 21) | 4.3 (2.4; 6.2) | 4.8 (2.9; 6.8) | 6.0 (3.8; 8.2) | 6.9 (4.6; 9.0) | 0.30 | 0.16 | 0.78 |
| Overall sleep quality (0; 3) | 1.0 (0.5; 1.5) | 0.7 (0.2; 1.2) | 1.2 (0.6; 1.7) | 1.0 (0.4; 1.5) | 0.20 | 0.57 | 0.83 |
| Sleep latency (0; 3) | 0.6 (0.1; 1.1) | 0.8(0.3; 1.4) | 0.6 (0.06; 1.2) | 1.0 (0.3; 1.6) | 0.28 | 0.87 | 0.84 |
| Sleep duration (0; 3) | 0.08 (−0.2;0.3) | 0.45 (0.1; 0.7) | 0.3 ( −0.004; 0.6) | 0.2 (−0.1;0.5) | 0.30 | 0.95 | 0.06 |
| Sleep efficiency (0; 3) | 0.1( −0.4;0.7) | 0.4 ( −0.1; 1.0) | 0.6 (−0.005; 1.3) | 1.3 (0.6;2.0) | 0.07 | 0.07 | 0.50 |
| Sleep disturbances (0; 3) | 1.3 (0.9; 1.6) | 1.1 (0.8; 1.5) | 1.22 (0.8; 1.6) | 1.1 (0.7; 1.5) | 0.44 | 0.66 | 0.89 |
| Sleep medication use (0; 3) | 0.42 (−0.3; 1.1) | 0.35 (−0.3; 1.0) | 1.33 (0.5; 2.1) | 1.0 (0.1; 1.8) | 0.34 | 0.13 | 0.51 |
| Daytime dysfunction (0; 3) | 0.5 (0.2;0.9) | 0.7 (0.4;1.1) | 0.5 (0.4; 1.1) | 1.2 (0.7; 1.6) | <0.01 | 0.40 | 0.13 |
Values are described in mean (95 confidence interval). Abbreviations: INT: interaction. JSLE: juvenile systemic lupus erythematosus
Effects of a 12-week home-based exercise training program on Strengths and Difficulties Questionnaire (SDQ), Pediatric Quality of Live Inventory 4.0 (PedsQL 4.0), and Pittsburgh Sleep Quality Index (PSQI) in adolescents with juvenile idiopathic arthritis.
| Control group | Intervention group | p value | |||||
|---|---|---|---|---|---|---|---|
| Domains (score) | Mean baseline (95% CI) | Mean post (95% CI) | Mean baseline (95% CI) | Mean post (95% CI) | TIME | GROUP | INT |
| Total difficulties score (0; 40) | 15.0 (11.9; 18.0) | 13.8 (10.7; 16.8) | 14.6 (11.4; 17.8) | 13.2 (9.9; 16.4) | 0.33 | 0.78 | 0.93 |
| Emotional problems (0; 10) | 4.7 (3.5; 5.9) | 4.0 (2.8; 5.2) | 4.3 (3.0; 5.6) | 4.7 (3.4; 6.0) | 0.82 | 0.80 | 0.33 |
| Conduct problems (0; 10) | 2.5 (1.5; 3.4) | 2.8 (1.9; 3.7) | 3.2 (2.2; 4.2) | 2.0 (1.0; 2.9) | 0.30 | 0.88 | 0.05 |
| Hyperactivity/inattention (0; 10) | 4.7 (3.5; 5.9) | 4.0 (2.7; 5.2) | 4.8 (3.5; 6.1) | 4.2 (2.9; 5.5) | 0.26 | 0.77 | 0.88 |
| Peer problems (0; 10) | 2.6 (1.6; 3.6) | 2.8 (1.8; 3.8) | 2.2 (1.1; 3.2) | 2.1 (1.0; 3.1) | 0.89 | 0.30 | 0.76 |
| Prosocial (0; 10) | 8.1 (7.0; 9.1) | 6.9 (5.9; 7.9) | 8.1 (7.0; 9.2) | 8.5 (7.4; 9.6) | 0.46 | 0.15 | 0.12 |
| Impact score (0; 10) | 0.94 (0.1; 1.7) | 0.19 (−0.5; 0.9) | 1.9 (1.0; 2.7) | 0.7( −0.04; 1.6) | 0.01 | 0.08 | 0.58 |
| PedsQL total scale score (0; 100) | 72.4 (64.9; 80.0) | 78.0(70.5; 85.6) | 63.1 (55.0; 71.2) | 64.5 (56.4; 72.6) | 0.29 | 0.01 | 0.52 |
| Physical health summary score (0; 100) | 76.3 (66.0; 86.7) | 74.4(64.0; 84.7) | 65.4 (54.3; 76.4) | 64.9 (53.8; 76.0) | 0.79 | 0.10 | 0.86 |
| Emotional functioning (0; 100) | 60.0 (51.5; 68.4) | 79.0 (70.6; 87.5) | 50.7 (41.6; 59.7) | 57.8 (48.8; 66.8) | <0.01 | <0.01 | 0.14 |
| Social functioning (0; 100) | 80.6 (72.9; 88.2) | 89.0 (81.4; 96.7) | 75.0 (66.8; 83.1) | 77.1 (68.9; 85.3) | 0.18 | 0.03 | 0.42 |
| School functioning (0; 100) | 65.0 (55.6; 74.3) | 77.1(67.8; 86.4) | 57.1 (47.1; 67.0) | 57.5 (47.5; 67.4) | 0.15 | 0.01 | 0.17 |
| Psychosocial health summary (0; 100) | 68.5 (61.9; 75.0) | 81.7 (75.2; 88.3) | 60.9 (53.9; 67.9) | 64.1 (57.1; 71.1) | 0.01 | <0.01 | 0.12 |
| PSQI total score (0; 21) | 5.3 (3.8; 6.9) | 3.1 (1.5; 4.6) | 6.4 (4.7; 8.0) | 4.2 (2.6; 5.9) | <0.01 | 0.94 | 0.66 |
| Overall sleep quality (0; 3) | 1. 0 (0.6; 1.3) | 0.6 (0.3; 1.0) | 1.0 (0.72; 1.4) | 0.64 (0.2; 0.9) | <0.01 | 0.76 | 0.66 |
| Sleep latency (0; 3) | 1.0 (0.6;1.4) | 0.6 (0.2; 1.0) | 1.5 (1.0; 1.9) | 0.8 (0.4; 1.2) | 0.01 | 0.14 | 0.61 |
| Sleep duration (0; 3) | 0.3 (0.007; 0.6) | 0.06 (−0.2; 0.3) | 0.50 (0.1; 0.8) | 0.2 ( −0.04; 0.6) | 0.09 | 0.25 | 0.89 |
| Sleep efficiency (0; 3) | 0.6 (0.1; 1.0) | 0.50 (0.03; 0.9) | 0.7 (0.2; 1.2 | 0.36 (−0.1; 0.8) | 0.25 | 0.97 | 0.53 |
| Sleep disturbances (0; 3) | 1.0 (0.9; 1.1) | 0.8 (0.7; 1.0) | 1.0 (0.9; 1.2) | 1.0 (0.8; 1.1) | 0.05 | 0.33 | 0.36 |
| Sleep medication use (0; 3) | 0.6 (0.1; 1.2) | 0.1 ( −0.4; 0.6) | 0.7 (0.1; 1.2) | 0.7 (0.1; 1.2) | 0.21 | 0.34 | 0.21 |
| Daytime dysfunction (0; 3) | 0.6 (0.2; 0.9) | 0.2 (−0.09; 0.5) | 0.7 (0.4; 1.1) | 0.4 (0.06; 0.7) | 0.04 | 0.34 | 0.96 |
Values are described in mean (95 confidence interval). INT: interaction; JIA: juvenile idiopathic arthritis